1-18 of 18
Alex Z. Fu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Healthcare Resource Utilization and Costs Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Contemporary US Claims

Scott F. Huntington, Hsien-Yen Chang, Alex Z. Fu, Christina Loefgren, Xiaoxiao Lu
Journal: Blood
Blood (2023) 142 (Supplement 1): 2348.
https://doi.org/10.1182/blood-2023-181909
Published: 2023
Journal Articles

Real-World Treatment Patterns and Overall Survival Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Claims Data

Scott F. Huntington, Hsien-Yen Chang, Alex Z. Fu, Christina Loefgren, Xiaoxiao Lu
Journal: Blood
Blood (2023) 142 (Supplement 1): 2428.
https://doi.org/10.1182/blood-2023-178755
Published: 2023
Journal Articles

Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma

Doris K. Hansen, Santosh Gautam, Marie-Hélène Lafeuille, Carmine Rossi, Bronwyn Moore, Anabelle Tardif-Samson, Philippe Thompson-Leduc, Alex Z. Fu, Annelore Cortoos, Shuchita Kaila, Rafael Fonseca
Journal: Blood
Blood (2023) 142 (Supplement 1): 543.
https://doi.org/10.1182/blood-2023-187233
Published: 2023
Journal Articles

Real-World Patient Profile and Step-up Dosing Process of Early Initiators of Teclistamab for Multiple Myeloma in US Hospitals - an Updated Analysis Using Premier Healthcare Database

Carlyn Rose Tan, Nina Kim, Eric Chinaeke, Laura Hester, Jessica Fowler, Dina Gifkins, Dee Lin, Sian Walker, Alex Z. Fu, Bingcao Wu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3792.
https://doi.org/10.1182/blood-2023-178896
Published: 2023
Journal Articles

Real-World Clinical Outcomes Among Triple-Class Exposed Multiple Myeloma Patients and Subgroups in the US Oncology Network

Robert M. Rifkin, Jennifer S. Harper, Hoa H. Le, Alex Z. Fu, Saurabh N. Patel, Xinke Zhang, Ira L. Zackon
Journal: Blood
Blood (2023) 142 (Supplement 1): 7362.
https://doi.org/10.1182/blood-2023-186616
Published: 2023
Journal Articles

Systematic Literature Review and Meta-Analysis of Comparative Clinical Evidence Investigating Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) As First-Line Treatment for Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Lucio Gordan, Rohan Medhekar, Alex Z. Fu, Abril Oliva Ramirez, Nicolle Bonar, Bao-Ngoc Nguyen, Michaela Spence, Rebecca McTavish, Tim Disher, Shuchita Kaila, Anjan J. Patel
Journal: Blood
Blood (2023) 142 (Supplement 1): 1963.
https://doi.org/10.1182/blood-2023-180829
Published: 2023
Journal Articles

Real-World Treatment Patterns and Clinical Outcomes Among Triple-Class Exposed and B-Cell Maturation Antigen (BCMA) Exposed Multiple Myeloma Patients

Hira Mian, Jennifer S. Harper, Hoa H. Le, Alex Z. Fu, Saurabh N. Patel, Xinke Zhang, Rafael Fonseca
Journal: Blood
Blood (2023) 142 (Supplement 1): 542.
https://doi.org/10.1182/blood-2023-189229
Published: 2023
Journal Articles

Burden of Hospitalization before and after a Disease Progression Following Triple-Class Exposure in Patients with Relapsed and Refractory Multiple Myeloma

Jennifer S Harper, Alex Z. Fu, Dee Lin, Bingcao Wu, Nina Kim, Savanna Ledford, Sundar Jagannath
Journal: Blood
Blood (2022) 140 (Supplement 1): 5214–5215.
https://doi.org/10.1182/blood-2022-167617
Published: 2022
Journal Articles

Characteristics and Treatment of Patients with Multiple Myeloma Who Received Daratumumab in a Large Claims Database in the United States

Snow X Feng, Alex Z. Fu, Vipin Khare, Augustina Ogbonnaya, Shuchita Kaila
Journal: Blood
Blood (2021) 138 (Supplement 1): 4031.
https://doi.org/10.1182/blood-2021-149001
Published: 2021
Journal Articles

Real-World Patient Characteristics and Treatment Outcomes Among Newly Diagnosed Multiple Myeloma Patients Initiating Daratumumab, Lenalidomide, and Dexamethasone As First-Line Therapy

Ming-Hui Tai, Qian Cai, Alex Z. Fu, Vipin Khare, Shuchita Kaila
Journal: Blood
Blood (2021) 138 (Supplement 1): 1979.
https://doi.org/10.1182/blood-2021-149002
Published: 2021
Journal Articles

Characteristics and Outcomes of Non-Transplanted Patients with Newly Diagnosed Multiple Myeloma (NDMM) Initiating Treatment with Bortezomib, Lenalidomide, and Dexamethasone (VRd) As First-Line of Therapy

Rohan Medhekar, Tao Ran, Alex Z. Fu, Sharmila Patel, Shuchita Kaila
Journal: Blood
Blood (2021) 138 (Supplement 1): 3782.
https://doi.org/10.1182/blood-2021-153416
Published: 2021
Journal Articles

Real-World Use of Maintenance Therapy and Associated Outcomes Following Autologous Stem Cell Transplant in US Patients with Newly Diagnosed Multiple Myeloma

Eric M. Ammann, PhD, Annette Lam, MSc, Wenze Tang, MPH, Tobias Kampfenkel, MD, Mohit Sharma, Charlene Lee, MSc, Shuchita Kaila, PhD, Alex Z. Fu, PhD, Kathleen Gray, PhD, Jianming He, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-139882
Published: 2020
Journal Articles

Treatment Patterns and Adherence Among Patients with Myelodysplastic Syndromes Receiving Deferasirox As Iron Chelation Therapy: A Real World Medicare Database Study

Alex Z Fu, PhD, Yanni Hao, PhD, Austin Coe, Ying Qiu, PhD, Zhiyi Li, Becky Hanna, Jackson Tang, Brian M. Elliott, MD, Carole Paley, MD
Journal: Blood
Blood (2016) 128 (22): 4759.
https://doi.org/10.1182/blood.V128.22.4759.4759
Published: 2016
Journal Articles

Clinical Outcomes Among Patients with Myelodysplastic Syndromes Treated with Iron Chelation Therapy: A Real World Medicare Database Study

Yanni Hao, PhD, Alex Z Fu, PhD, Austin Coe, Ying Qiu, PhD, Zhiyi Li, Becky Hanna, Jackson Tang, Brian M. Elliott, MD, Carole Paley, MD
Journal: Blood
Blood (2016) 128 (22): 2396.
https://doi.org/10.1182/blood.V128.22.2396.2396
Published: 2016
Journal Articles

The Value of Post-Remission Therapy in Older Adults with Acute Myeloid Leukemia (AML).

Mikkael A. Sekeres, MD, MS, Alex Z Fu, PhD, Marc Earl, PharmD, Matt Kalaycio, MD, Anjali Advani, MD, Yogen Saunthararajah, M.D., Ronald Sobecks, MD, Edward Copelan, MD
Journal: Blood
Blood (2009) 114 (22): 1043.
https://doi.org/10.1182/blood.V114.22.1043.1043
Published: 2009
Journal Articles

Race and Intensity of Post-Remission Therapy in Acute Myeloid Leukemia (AML).

Anna K Brady, BS, BA, Alex Z Fu, PhD, Marc Earl, PharmD, Matt Kalaycio, Anjali Advani, MD, Yogen Saunthararajah, M.D., Ronald Sobecks, Edward Copelan, MD, Mikkael A. Sekeres, MD, MS
Journal: Blood
Blood (2009) 114 (22): 1012.
https://doi.org/10.1182/blood.V114.22.1012.1012
Published: 2009
Journal Articles

Impact of Weekend Admissions on Quality of Care and Outcomes in Patients with Acute Myeloid Leukemia (AML).

Nelli Bejanyan, MD, Alex Z Fu, PhD, Rao Fu, Matt Kalaycio, MD, Anjali Advani, MD, Ronald Sobecks, MD, Edward A. Copelan, Mikkael A. Sekeres, MD, MS
Journal: Blood
Blood (2008) 112 (11): 1942.
https://doi.org/10.1182/blood.V112.11.1942.1942
Published: 2008
Journal Articles

A Decision Analysis To Determine the Appropriate Treatment for Low-Risk Myelodysplastic Syndromes.

Mikkael A. Sekeres, MD, Alex Z. Fu, PhD, Jaroslaw P. Maciejewski, MD, PhD, Ali-Raza Golshayan, MD, Matt Kalaycio, MD, Michael W. Kattan, PhD
Journal: Blood
Blood (2005) 106 (11): 2533.
https://doi.org/10.1182/blood.V106.11.2533.2533
Published: 2005